Cellular therapies represent one of the most promising yet complex forms of treatment in modern medicine. These "living medicines" hold significant healing potential, particularly in areas such as cancer and infection medicine. The development of chimeric antigen receptor (CAR)-modified immune cells has already showcased impressive progress, gaining approval as a treatment for blood cancers. Anticipated similar advancements hold promise for more prevalent cancers and infections.

Nevertheless, translating these promising preclinical research findings into concrete clinical applications is a formidable challenge. Success has been achieved in only a few individual cases in Bavaria, primarily due to the scarcity of combined expertise and technologies in this field. Consequently, developers for specific applications often find themselves starting high up in the clinical transfer chain.

To address these challenges, the universities of Munich and Würzburg have joined forces through BAYCELLator. This collaboration aims not only to advance cell therapeutics but also to develop fundamental technologies, referred to as "enablers," with the potential for long-term benefits in the future of cellular therapies in Bavaria. Initially focusing on hematology, oncology, and infection medicine, the consortium plans to lay the groundwork for establishing a Bavaria-wide cell therapy network in the long term.

The BAYCELLator Consortium is headquartered in the Division of Clinical Pharmacology at the University Hospital of LMU Munich (KUM).